Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards for its newly hired Chief Legal Officer, Jane Wright-Mitchell, approved March 23, 2026 under the 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The grants include non-qualified stock options to purchase 56,850 Class A shares at an exercise price of $40.73 (Vera's March 23 closing price) and restricted stock units underlying 42,403 Class A shares. Options vest over four years (25% at first anniversary, then monthly over 36 months). RSUs vest 25% on each anniversary beginning May 20, 2026. Awards are subject to the Inducement Plan and award agreements.

Key Figures

Grant date: March 23, 2026 Option exercise price: $40.73 Stock options granted: 56,850 shares +5 more

8 metrics

Grant date March 23, 2026 Inducement stock option and RSU grant date

Option exercise price $40.73 Exercise price equals VERA closing price on March 23, 2026

Stock options granted 56,850 shares Non-qualified stock options under 2024 Inducement Plan

RSUs granted 42,403 shares Restricted stock units under 2024 Inducement Plan

Option vesting period 4 years 25% after one year, remainder monthly over 36 months

RSU vesting period 4 years 25% of shares vest each year on May 20 starting 2026

Initial cliff vest 25% First-year vesting portion for both options and RSUs

Monthly vesting duration 36 months Remaining stock options vest monthly after first year

Market Reality Check

Price: $38.86 Vol: Volume 625,621 vs 20-day ...

low vol

$38.86 Last Close

Volume Volume 625,621 vs 20-day average 1,283,136 (relative volume 0.49). low

Technical Price 40.26 trading above 200-day MA at 32.97, about 28% below 52-week high 56.05.

Peers on Argus

VERA was down 0.86% while key biotech peers like AUPH (+3.18%), ARDX (+2.99%) an...

VERA was down 0.86% while key biotech peers like AUPH (+3.18%), ARDX (+2.99%) and VRDN (+1.29%) were positive, indicating stock-specific trading rather than a sector-wide move.

Historical Context

5 past events · Latest: Mar 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 25	C-suite appointment	Positive	+1.0%	Named Jane Wright-Mitchell Chief Legal Officer with deep life-sciences experience.
Mar 06	Employee inducement grants	Neutral	-0.3%	Inducement stock options and RSUs granted to six new employees under 2024 plan.
Mar 05	Board appointment	Positive	-2.0%	Added experienced biopharma executive Christopher Hite to board ahead of launch.
Feb 26	Earnings and pipeline	Positive	+1.6%	Reported positive Phase 3 data, FDA priority review and substantial 2025 financing.
Feb 24	Investor conferences	Neutral	+0.7%	Announced participation in multiple March investor conferences and webcasts.

Pattern Detected

Recent news has focused on leadership additions, inducement awards, and major clinical/financial milestones, with share reactions mostly modest and generally aligned with the positive tone, except for a board appointment that saw a short-term decline.

Recent Company History

Over the last month, Vera reported several governance and strategic updates. Leadership appointments on Mar 5 and Mar 25, 2026 and related inducement grants on Mar 3 and Mar 23 were layered onto a stronger backdrop of positive Phase 3 atacicept data and a Jul 7, 2026 PDUFA date disclosed on Feb 26, 2026. These were accompanied by significant financings and cash levels, plus active investor outreach via March conferences.

Market Pulse Summary

This announcement details standard inducement equity awards to Vera’s new Chief Legal Officer under ...

Analysis

This announcement details standard inducement equity awards to Vera’s new Chief Legal Officer under Nasdaq Listing Rule 5635(c)(4), including 56,850 options at an exercise price of $40.73 and 42,403 RSUs, each vesting over four years. It follows recent leadership changes and prior inducement grants, reinforcing a pattern of using equity to attract senior talent. Investors may track future filings and governance updates alongside the company’s clinical and regulatory milestones.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, restricted stock units, rsus, +3 more

7 terms

nasdaq listing rule 5635(c)(4) regulatory

"grants under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"granted inducement awards consisting of non-qualified stock options"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units (RSUs) underlying 42,403 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"and restricted stock units (RSUs) underlying 42,403 shares"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

exercise price financial

"has an exercise price per share equal to $40.73"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting commencement date technical

"on the first anniversary of the applicable vesting commencement date"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

inducement plan financial

"under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan)"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 56,850 shares of Class A common stock and restricted stock units (RSUs) underlying 42,403 shares of Class A common stock to Jane Wright-Mitchell, Vera’s new Chief Legal Officer under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option granted on March 23, 2026 has an exercise price per share equal to $40.73, Vera Therapeutics’ closing trading price on March 23, 2026. The stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The RSU award will vest over four years, with 25% of the underlying shares vesting on each anniversary of May 20, 2026, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

Who received inducement awards from Vera Therapeutics (VERA) on March 23, 2026?

Jane Wright-Mitchell, Vera Therapeutics' new Chief Legal Officer, received the inducement awards. According to Vera Therapeutics, the Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4) as material to her employment.

What equity did Vera Therapeutics (VERA) grant on March 23, 2026 and at what exercise price?

Vera granted non-qualified stock options for 56,850 shares and RSUs for 42,403 shares. According to Vera Therapeutics, the option exercise price equals the March 23 closing price of $40.73 per share.

How do the stock option vesting terms for Vera Therapeutics (VERA) inducement awards work?

The stock option vests over four years: 25% at the first anniversary, then monthly over 36 months. According to Vera Therapeutics, continued service through each vesting date is required for vesting eligibility.

What are the RSU vesting terms for the Vera Therapeutics (VERA) inducement grant?

The RSUs vest over four years with 25% of underlying shares vesting each anniversary starting May 20, 2026. According to Vera Therapeutics, vesting is subject to the recipient’s continued service through each anniversary date.

Under what plan and Nasdaq rule were the Vera Therapeutics (VERA) inducement awards granted?

The awards were granted under the Vera Therapeutics 2024 Inducement Plan and approved under Nasdaq Listing Rule 5635(c)(4). According to Vera Therapeutics, the Compensation Committee deemed the grants material to the new hire’s employment.